Conservative management of endometrial cancer: a survey amongst European clinicians
- PMID: 29943129
- DOI: 10.1007/s00404-018-4820-7
Conservative management of endometrial cancer: a survey amongst European clinicians
Abstract
Objective: To investigate differences and similarities in the clinical approach of young clinicians managing women with endometrial cancer (EC) conservatively.
Methods: A web-based survey was carried out. A platform of the European Network of Young Gynaecological Oncologists (ENYGO) database was used. A 38-item multiple-choice questionnaire was used to evaluate current practice in fertility-sparing management of EC. The survey covered investigations, treatment options, follow-up and management of recurrence and future family planning. Descriptive statistics were used.
Results: Overall, 116 out of 650 (17.84%) ENYGO members responded to the survey. In 92 (79.3%) centres, the caseload of early stage EC treated conservatively was less than 10 per year. One hundred and seven responders (93.8%) believe that treatment with progestins could be offered in grade 1 EC without myometrial invasion, but a minority would recommend it even for grade 2 tumours with no myometrial invasion or grade 1 with superficial invasion. The diagnostic tool for establishing grade of tumour was hysteroscopy with dilatation and curettage in 64 (55%) centres. Medroxyprogesterone acetate represents the most commonly prescribed progestogen (55, 47.4%). In 78 (67.2%) centres, a repeat endometrial biopsy was offered after 3 months of treatment commencement. Recurrences are treated mostly with hysterectomy (81, 69.9%) with only a small number of responders recommending to repeat progestin treatment. Lynch syndrome is a contraindication for conservative management in half of the responders (57, 49.1%). Most clinicians agree that patients should be referred promptly for assisted reproductive techniques once complete response has been achieved (68, 58.6%).
Conclusions: Our study shows that conservative management is increasingly offered to women affected by early stage EC wishing to preserve their fertility. Further studies and joint registries are required to evaluate safety and effectiveness of this approach in this probably growing number of patients.
Keywords: Assisted reproduction; Conservative management; Endometrial cancer; Pregnancies; Progestins.
Comment in
-
The reproductive prognosis of women considering fertility preservation for early stage endometrial cancer.Arch Gynecol Obstet. 2020 Nov;302(5):1305-1306. doi: 10.1007/s00404-018-5028-6. Epub 2019 Jan 4. Arch Gynecol Obstet. 2020. PMID: 30607588 No abstract available.
Similar articles
-
Occult myometrial recurrence after progesterone therapy to preserve fertility in a young patient with endometrial cancer.Fertil Steril. 2008 Mar;89(3):724.e1-3. doi: 10.1016/j.fertnstert.2007.03.068. Epub 2007 Jun 13. Fertil Steril. 2008. PMID: 17570366
-
Fertility preserving management of early endometrial cancer in a patient cohort at the department of women's health at the university of Tuebingen.Arch Gynecol Obstet. 2021 Jul;304(1):215-221. doi: 10.1007/s00404-020-05905-8. Epub 2021 Feb 19. Arch Gynecol Obstet. 2021. PMID: 33606091 Free PMC article.
-
Oncologic and pregnancy outcomes of fertility-sparing treatment with medroxyprogesterone acetate in women with premalignant and malignant endometrial lesions: A case series.Eur J Surg Oncol. 2025 Apr;51(4):109570. doi: 10.1016/j.ejso.2024.109570. Epub 2024 Dec 30. Eur J Surg Oncol. 2025. PMID: 39765374
-
Hysteroscopic resection in the management of early-stage endometrial cancer: report of 2 cases and review of the literature.J Minim Invasive Gynecol. 2015 Jan;22(1):34-9. doi: 10.1016/j.jmig.2014.08.782. Epub 2014 Sep 6. J Minim Invasive Gynecol. 2015. PMID: 25196160 Review.
-
Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.Arch Gynecol Obstet. 2015 Jan;291(1):151-7. doi: 10.1007/s00404-014-3417-z. Epub 2014 Aug 14. Arch Gynecol Obstet. 2015. PMID: 25118836 Review.
Cited by
-
Improving response to progestin treatment of low-grade endometrial cancer.Int J Gynecol Cancer. 2020 Nov;30(11):1811-1823. doi: 10.1136/ijgc-2020-001309. Epub 2020 May 6. Int J Gynecol Cancer. 2020. PMID: 32381512 Free PMC article. Review.
-
Fertility-Sparing Approaches in Atypical Endometrial Hyperplasia and Endometrial Cancer Patients: Current Evidence and Future Directions.Int J Mol Sci. 2022 Feb 25;23(5):2531. doi: 10.3390/ijms23052531. Int J Mol Sci. 2022. PMID: 35269674 Free PMC article. Review.
-
ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma.Hum Reprod Open. 2023 Feb 6;2023(1):hoac057. doi: 10.1093/hropen/hoac057. eCollection 2023. Hum Reprod Open. 2023. PMID: 36756380 Free PMC article.
-
A case of incidental endometrial adenocarcinoma diagnosed in early pregnancy and managed conservatively.Gynecol Oncol Rep. 2019 Mar 27;28:101-103. doi: 10.1016/j.gore.2019.03.015. eCollection 2019 May. Gynecol Oncol Rep. 2019. PMID: 30993161 Free PMC article.
-
Fertility-sparing treatment outcomes using immune checkpoint inhibitors in endometrial cancer patients with Lynch syndrome.J Gynecol Oncol. 2025 Jul;36(4):e59. doi: 10.3802/jgo.2025.36.e59. Epub 2025 Jan 3. J Gynecol Oncol. 2025. PMID: 39853260 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources